RxDoctor Payments Data

Barbara Hall, NP

Acute Care · Atlanta, GANPI 1730320870

Payments from drug & device makers

$1,637in general payments, 2019–2025

Across 22 payments — averaging $74.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$577
  • AbbVie$173
  • Neurocrine Biosciences, Inc.$134
  • Jazz Pharmaceuticals Inc.$129
  • Cvrx, Inc.$126
  • Insmed, Inc.$125
  • plus $373 from 4 others

What the payments were for

  • Food & beverage$1,637100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,637 in reported general payments places this provider in the 80th percentile of 679 acute care providers in Georgia.

See all acute care providers in Georgia

Medicare billing

Part B allowed, 2024
$67,263
Medicare patients
189
Services billed
1,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide39$54,999
JardianceEmpagliflozin23$36,285
TrulicityDulaglutide29$32,967
EliquisApixaban27$28,929
FarxigaDapagliflozin Propanediol12$9,046
Wixela InhubFluticasone Propion/Salmeterol13$1,914
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$1,648
Valsartan62$1,636
Rosuvastatin Calcium113$1,593
Losartan Potassium119$1,581
Atorvastatin Calcium134$1,529
Amlodipine Besylate175$1,002
Pravastatin Sodium65$952
Nifedipine ErNifedipine20$898
SynthroidLevothyroxine Sodium12$879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$173$87912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 679 acute care providers in Georgia.

Other acute care in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →